Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Patients' expression of CEACAM5 might hold the key to activity after all.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.